WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Clarapath, a medical robotics company modernizing and transforming how pathology laboratories process tissue, announced a $36 million Series B-1 funding round led by Northwell Ventures. Additional new strategic investors participated in the financing, including CU Healthcare Innovation Fund, Mayo Clinic, and Ochsner Ventures, bringing the company's total funding to $75 million..

纽约州怀特普莱恩斯（商业新闻短讯）--克拉拉帕斯是一家医疗机器人公司，正在现代化和改造病理学实验室处理组织的方式，他宣布了由Northwell Ventures牵头的一轮3600万美元的B-1系列融资。。。

“Our strategic investors share in our mission to significantly overhaul this critical aspect of patient care that has long been overlooked,” said Eric Feinstein, CEO of Clarapath. “As labs adopt digital pathology downstream, automation in prior steps is crucial to establish consistent results and provide best-in-class samples for diagnostic review.

Clarapath首席执行官埃里克·范斯坦（EricFeinstein）表示：“我们的战略投资者与我们的使命是对长期以来被忽视的病人护理的这一关键方面进行重大改革。”。“由于实验室在下游采用数字病理学，因此先前步骤的自动化对于建立一致的结果并为诊断审查提供一流的样本至关重要。

Our automation and new digital tools capture and aggregate never-before-seen data, ultimately benefiting patients with faster results and less subjectivity.”.

我们的自动化和新的数字工具捕获并汇总了前所未有的数据，最终使患者受益更快，主观性更小。”。

The discipline of pathology involves the microscopic examination of cells and tissue, underpinning the research, diagnosis and treatment pathway of nearly every disease type including: cancer; autoimmune conditions; degenerative diseases and others. Currently in the US, more than 12 million human and veterinary biopsies are performed each year, with millions more for biopharmaceutical drug safety.

病理学学科涉及细胞和组织的显微镜检查，支持几乎每种疾病类型的研究，诊断和治疗途径，包括：癌症；自身免疫性疾病；退行性疾病等。目前在美国，每年进行超过1200万次人体和兽医活检，其中数百万次用于生物制药药物安全。

Today, a multi-prong crisis exists in laboratories that is driven by severe labor shortages, rising caseloads and an antiquated, manual process of preparing tissue samples..

如今，由于严重的劳动力短缺、不断增加的工作量以及陈旧的手工制备组织样本的过程，实验室面临着多方面的危机。。

“Innovation is embedded in Northwell’s culture and integral to the way we approach investment in novel solutions which improve patient care and lower cost.” said Rich Mulry, CEO of Northwell Holdings. “We identified Clarapath seven years ago as a company with a bold vision to radically change laboratory medicine and are committed to continued support of their progressive journey which will transform medical diagnostics.”.

Northwell Holdings首席执行官Rich Mulry表示：“创新植根于Northwell的文化中，是我们在改进患者护理和降低成本的新型解决方案投资方式中不可或缺的一部分。”。“七年前，我们将克拉拉巴斯确定为一家具有从根本上改变实验室医学的大胆愿景的公司，并致力于继续支持他们的进步之旅，这将改变医学诊断。”。

Robotics and automated systems have been introduced in healthcare settings as a way to alleviate workforce issues and standardize, however most of the progress has been aimed at surgical robots or physical rehabilitation. With this latest round of funding, Clarapath is poised to be the first US-based company to develop and deploy a new category of ground-breaking healthcare robotics, machine vision and digital automation tools, elevating the standard for hospitals and patients..

机器人技术和自动化系统已被引入医疗机构，作为缓解劳动力问题和标准化的一种方式，但大多数进展都是针对手术机器人或身体康复。凭借这一最新一轮资金，克拉拉帕斯有望成为美国第一家开发和部署新一类开创性医疗机器人、机器视觉和数字自动化工具的公司，从而提高医院和患者的标准。。

“For too long, pathology laboratories have not seen the level of technology innovation that other areas of medicine have seen,” said Gregg Sossaman, M.D., Chair of Pathology and Laboratory Medicine at Ochsner Health and incoming President of the American Society for Clinical Pathology. “Clarapath demonstrates the right mix of technical, robotic expertise coupled with healthcare workflow experience.”.

“很长一段时间以来，病理学实验室都没有看到其他医学领域所看到的技术创新水平，”医学博士格雷格·索萨曼（GreggSossaman）说，他是Ochsner Health病理学和实验医学主席，也是美国临床病理学学会（American Society For Clinical pathology）新任主席。“克拉拉帕斯展示了技术、机器人专业知识与医疗保健工作流程经验的正确结合。”。

With this new capital, Clarapath will further accelerate the commercialization of SectionStar™. The company will also leverage the funds to expand its sales and service, precision manufacturing capabilities as well as continue its robust R&D pipeline.

凭借这一新资本，克拉拉帕斯将进一步加速SectionStar™的商业化。该公司还将利用这些资金扩大其销售和服务、精密制造能力，并继续其强大的研发渠道。

“Together, we are building the foundation for a 'lab of the future' that incorporates end-to-end automation, robotics, and AI to the patient tissue lifecycle,” says Joaquín García, M.D., chair of the division of Anatomic Pathology within Mayo Clinic’s Department of Laboratory Medicine and Pathology and chair of Mayo Clinic's Digital Pathology Program..

梅奥诊所检验医学与病理学系解剖病理学系主任兼梅奥诊所数字病理学项目主席Joaquin García医学博士说：“我们正在共同为‘未来实验室’奠定基础，该实验室将端到端自动化、机器人技术和人工智能纳入患者组织的生命周期。”。。

About Clarapath

关于克拉拉帕斯

Clarapath is a medical robotics company aimed at catalyzing change in the way pathology laboratories work. Clarapath's SectionStar is the first (pending US launch) all-in-one tissue sectioning and transfer system that dramatically increases capacity, reliability, and consistency while minimizing the need for highly skilled labor.

Clarapath是一家医疗机器人公司，旨在促进病理学实验室工作方式的改变。Clarapath的SectionStar是第一个（即将在美国推出）一体化组织切片和转移系统，可显着提高容量，可靠性和一致性，同时最大程度地减少对高技能劳动力的需求。

The company is headquartered and runs its medical device development in Hawthorne, NY. It has a CLIA-certified laboratory that serves clinical and non-clinical organizations. For more information, visit https://www.clarapath.com/.

该公司总部位于纽约州霍桑，负责医疗器械开发。它有一个CLIA认证的实验室，为临床和非临床组织服务。有关更多信息，请访问https://www.clarapath.com/.